The volatile biotech sector is experiencing extreme selling on Friday, pushing the NASDAQ down over 2%. Sr. Biotech Editor Adam Feuerstein says the sector rotation out of biotech has erased all the gains from the beginning of the year. The selling has gained in volume and speed as no one wants to be the last trader standing. Feuerstein thinks the selling could continue unless there is some big M&A news or a positive development on the biotech side to bring back investors.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Indices Don't Have Much in Common

Trader's Daily Notebook: 3 ETFs With Healthy Setups

Trader's Daily Notebook: Keeping a Short Leash